INVESTIGATION NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation into potential claims related to Aquestive Therapeutics, Inc. (NASDAQ: AQST) following a significant drop in the company’s stock value. On March 5, 2026, shares of Aquestive Therapeutics experienced an intraday decline of approximately 40% after the U.S. Food and Drug Administration (FDA) identified deficiencies in the Company’s New Drug Application (NDA) for Anaphylm, a proposed sublingual treatment for severe allergic reactions, including anaphylaxis.

The FDA's disclosure raised serious concerns about the application's approvability, which further complicated discussions about labeling and post-marketing requirements prior to the action date set for January 31, 2026. Given this setback, Faruqi & Faruqi is reaching out to investors who may have suffered significant financial losses associated with their holdings in Aquestive Therapeutics.

Faruqi & Faruqi has a strong track record in securities litigation, having recovered hundreds of millions of dollars for investors since its founding in 1995. Investors affected by the decline are encouraged to contact the firm’s partner, Josh Wilson, to discuss their legal rights and options for recourse. The firm is committed to providing confidential consultations and is well-equipped to handle potential securities claims.

For investors seeking more information regarding the investigation, they can visit the firm's dedicated webpage or contact them directly at the provided phone numbers. As this situation develops, Faruqi & Faruqi will provide updates through various social media platforms.

This investigation signifies an important opportunity for affected investors to explore legal avenues in response to the recent adverse developments at Aquestive Therapeutics.

The recent investigation announcement by Faruqi & Faruqi, LLP concerning Aquestive Therapeutics, Inc. (NASDAQ: AQST) has raised significant attention in the investment community, particularly following the sharp 40% decline in the company’s stock. The firm's investigation stems from the FDA's identification of deficiencies in the New Drug Application for Anaphylm, raising substantial concerns regarding the potential approvability of this crucial product designed for managing severe allergic reactions.

Investors suffering substantial losses may be weighing their legal options, as the investigation could unfold into broader implications concerning the company’s financial health and operational transparency. These developments compel potential and current investors to thoroughly assess their positions in Aquestive.

From a market perspective, the immediate reaction to this news indicates a bearish sentiment surrounding AQST stock, largely influenced by uncertainty regarding the FDA's next steps. As the PDUFA action date approaches on January 31, 2026, investors should remain vigilant. Failure to address the FDA's concerns may result in further price declines, whereas a resolution could pivot the stock in a positive direction.

For long-term investors, this incident serves as a reminder of the volatility often inherent in biotechnology stocks, where approvals can make or break a company's future prospects. Investors should consider diversifying their holdings to mitigate risks associated with single-product companies, especially those heavily reliant on regulatory approvals.

In conclusion, investors should monitor developments closely while taking heed of potential legal ramifications and market reactions. Engaging with financial advisors can also provide tailored strategies, allowing for adjustments based on risk tolerance and market outlook as the situation evolves.